Rare Diseases Symptoms Automatic Extraction
Home
A random Abstract
Our Project
Our Team
Antiviral activity of (+)-rutamarin against Kaposi's sarcoma-associated herpesvirus by inhibition of the catalytic activity of human topoisomerase II.
[primary effusion lymphoma]
Kaposi
's
sarcoma
-associated
herpesvirus
(
KSHV
)
is
an
etiological
agent
of
several
AIDS-associated
malignancies
,
including
Kaposi
's
sarcoma
(
KS
)
,
primary
effusion
lymphoma
(
PEL
)
,
and
multicentric
Castleman
's
disease
(
MCD
)
.
Its
lytic
replication
cycle
has
been
proven
to
be
critical
for
the
pathogenesis
of
KSHV-associated
diseases
.
In
KS
lesions
,
lytic
viral
replication
,
production
of
virion
particles
,
and
reinfection
of
endothelial
cells
are
essential
to
sustain
the
population
of
infected
cells
that
otherwise
would
be
quickly
lost
as
spindle
cells
divide
.
Thus
,
antivirals
that
block
KSHV
replication
could
be
a
strategy
in
the
treatment
of
KSHV-associated
diseases
.
However
,
there
is
no
effective
anti-
KSHV
drug
currently
available
.
Our
previous
work
showed
that
human
topoisomerase
II
(
Topo
II
)
is
indispensable
for
KSHV
lytic
replication
and
is
suggested
to
be
an
effective
target
for
antiviral
drugs
.
Here
,
we
report
the
discovery
and
characterization
of
a
novel
catalytic
inhibitor
of
human
Topo
II
α
,
namely
,
(
+
)
-
rutamarin
.
The
binding
mode
of
(
+
)
-
rutamarin
to
the
ATPase
domain
of
human
Topo
II
α
was
established
by
docking
and
validated
by
molecular
dynamics
(
MD
)
simulations
.
More
importantly
,
(
+
)
-
rutamarin
efficiently
inhibits
KSHV
lytic
DNA
replication
in
BCBL-
1
cells
with
a
half
-maximal
inhibitory
concentration
(
IC
50
)
of
1
.
12
μM
and
blocks
virion
production
with
a
half
-maximal
antiviral
effective
concentration
(
EC
50
)
of
1
.
62
μM
.
It
possesses
low
cytotoxicity
,
as
indicated
by
the
selectivity
index
(
SI
)
of
84
.
14
.
This
study
demonstrated
great
potential
for
(
+
)
-
rutamarin
to
become
an
effective
drug
for
treatment
of
human
diseases
associated
with
KSHV
infection
.
Diseases
Validation
Diseases presenting
"lytic replication cycle"
symptom
primary effusion lymphoma
You can validate or delete this automatically detected symptom
Validate the Symptom
Delete the Symptom